Skip to content

ACEi/ARB alone versus ACEi/ARB plus Steroids in the treatment of primary IgA nephropathy, a randomized multicenter controlled trial

ACEi/ARB alone versus ACEi/ARB plus Steroids in the treatment of primary IgA nephropathy, a randomized multicenter controlled trial

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-TRC-06000004
Enrollment
Unknown
Registered
2006-09-14
Start date
2006-01-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

primary IgA nephropathy

Interventions

group 1:treated with ACEI/ARB( ARB therapy is subjected to patients with cough after use of ACEI) Inhibace (cilazapril): start at 1.25mg/day, increase the dose by 1.25mg/day/week to 2.5-5mg/day Cozaar
group 2:Oral prednisone for 6 mos 0.8mg/kg/day x 8 wks Tapered 0.2mg/kg/day/mo in combination with ACEI/ARB

Sponsors

The First Hospital, Peking University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
16 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. age: 16 to 65 years old; 2. underwent renal biopsy within 1 year before start of trial; 3. 24 hour urinary protein excretion ranged between 1 to 7 g/d; 4. eGFR, evaluated by MDRD formula, should be higher than 30 ml/min.

Exclusion criteria

Exclusion criteria: 1. crescentic glomerulonephritis; 2. steroid therapy subjected within 1 year before trial; 3. malignant hypertension(DBP>130 mmHg and/or SBP>220mmHg), resistant to anti-hypertensive agents; 4. urinary protein excretion decrease below 1 g/l after run-in period; 5. Myocardial infarction or cerebrovascular accident in 6 months preceding the trial; 6. renovascular disease; 7. diabetes mellitus; 8. Malignancy, severe liver disease, refractory infection; 9. peptic ulcer in active disease phase; 10. pregnancy; 11. other contraindication to the use of ACEi/ ARB or corticosteroid; 12. alcohol abuse or drug addiction.

Design outcomes

Primary

MeasureTime frame
24 hour urinary protein excretion;serum creatinine;

Secondary

MeasureTime frame
blood pressure;urine routine analysis;Urea/BUN;

Countries

China

Contacts

Public ContactHong Zhang
hongzh@bjmu.edu.cn+86 0 13366610353

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026